Joseph Haas

Columbia

Senior Writer at The Pink Sheet

Senior Writer at Scrip

Adam Cole Bay-Bay. And Dusty would like to remind us all that that tennis ball is not going to throw itself.

Featured in: Favicon

informa.com (+5) Favicon

pharmamedtechbi.com Favicon

xconomy.com Favicon

citeline.com Favicon

invivo.citeline.com

Articles

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

6 days ago | insights.citeline.com | Lisa Takagi |Joseph Haas |Anju Ghangurde |Vibha Ravi

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding PlatformPlus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

1 week ago | insights.citeline.com | Joseph Haas

Sanofi Licenses Bispecific Candidates From AI-Driven EarendilDeal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil. Sanofi's pact with Earendil is the latest in several with AI-focused firms
Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome

1 week ago | insights.citeline.com | Joseph Haas

Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman SyndromePlus deals involving Spruce/BioMarin, Boehringer Ingelheim/Cue, Onconetix/Ocuvex, Allakos/Concentra, Sanofi/Nurix, Pfizer/Flagship Pioneering, Alcon/Aurion and more.
Ironwood To Consider All Options With Apraglutide Setback In SBS

1 week ago | insights.citeline.com | Joseph Haas

Ironwood To Consider All Options With Apraglutide Setback In SBSWith the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom. Ironwood is farther away now from its goal of getting apraglutide approved (Shutterstock)
Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

1 week ago | insights.citeline.com | Joseph Haas

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer NodsBristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC. BMS's Opdivo + Yervoy combo picks up two more US indications (Shutterstock)
Biotech Leaders Ponder Tariff Ramifications

1 week ago | insights.citeline.com | Joseph Haas |Mary Jo Laffler |Jessica Merrill

Biotech Leaders Ponder Tariff Ramifications Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare. Potential US tariffs' impact on pharmaceuticals has biotechs considering their options (Shutterstock)
First Quarter M&A Activity Rose On The Strength Of Three Deals

2 weeks ago | insights.citeline.com | Joseph Haas

First Quarter M&A Activity Rose On The Strength Of Three DealsThe biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate. Bolt-on acquisitions remained the order of the day in Q1, despite one $14bn+ deal • Source: Shutterstock
Aldeyra Expects Mid-2025 Refiling Of Reproxalap After Second CRL

2 weeks ago | insights.citeline.com | Joseph Haas

Aldeyra Expects Mid-2025 Refiling Of Reproxalap After Second CRLAldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies. Aldeyra hopes ongoing trials will provide data finally for FDA approval of reproxalap • Source: Shutterstock
BeiGene Ends Anti-TIGIT Development In Lung Cancer

3 weeks ago | insights.citeline.com | Joseph Haas

BeiGene Ends Anti-TIGIT Development In Lung CancerBeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies. BeiGene is moving on from the anti-TIGIT mechanism in immuno-oncology
Edgewise’s HCM Candidate May Provide Advantages Over BMS’s Camzyos

3 weeks ago | insights.citeline.com | Joseph Haas

Edgewise’s HCM Candidate May Provide Advantages Over BMS’s CamzyosWith new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy. Edgewise hopes to take on Bristol in HCM with a cardiac sarcomere modulator (Shutterstock)

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers: 283
Tweets: 6K
DMs Open: No

JH_Chase @JosephHaas2

30 Apr 23

RT @ChefRonSullivan: Let's just make the pipeline official #FlyEaglesFly #NFLDraft https://t.co/cIcm79W3gL

JH_Chase @JosephHaas2

26 Apr 23

So much for the narrative of Trae Young not showing up in big games @NBAonTNT

JH_Chase @JosephHaas2

24 Apr 23

At least the Union are back above the line and looking more like themselves. A long way to go but Saturday helped. I care about Champions League and other competitions too - but until you win MLS Cup, that should be an MLS club's top priority.